Incyte | INCY - 销售成本



金融业
股票价格
USD
资产
USD 7.87B
现金及等价物
USD 3.98B
销售成本
USD 104.96M
流动资产
USD 6.03B
流动负债
USD 1.31B
债务
USD 38.27M
EBIT
USD 700.4M
EBITDA
USD 778.57M
员工
2.62K
EPS每股收益
USD 3.09
股本和储备
USD 6.34B
销售毛利
USD 1.57B
债务利息支出
USD 582K
利息收入
USD 38.12M
贷款资金
USD 28.42M
市值
USD 28.6B
净收入
USD 585.61M
营业费用
USD 973.64M
营业利润
USD 700.4M
普通股股本
USD 200.98M
PE价格收益
14.45
税前利润
USD 751.51M
销售收入
USD 1.67B
销售和管理费用
USD 351.74M
股票
USD 112.54M
贸易债权人
USD 1.39B
应收帐款人
USD 1.13B


销售成本 更改 日
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agenus USD 642K 399K 2025-09
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amgen USD 1.87B 271M 2026-06
BioCryst Pharmaceuticals USD 3.84M 5.68M 2026-06
Biogen USD 945.1M 147.6M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Exelixis USD 20.66M 704K 2026-06
Gilead Sciences USD 1000M 445M 2026-06
Incyte USD 104.96M 457K 2026-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
MacroGenics USD 9.53M 585K 2026-03
Merck USD 3.14B 200M 2026-06
Moderna USD 93M 862M 2026-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Novartis USD 3.71B 251M 2026-06
Novartis USD 3.46B 83M 2026-03
Pfizer USD 4.09B 498M 2026-06
PTC Therapeutics USD 39.61M 23.31M 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06